Advanced Provision of Care

This study aims to evaluate advanced provision of an anti-progestin with a prostaglandin for future use (in the next 12 months) in individuals at risk for pregnancy but not desiring a pregnancy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pregnancy Related

Age range

18 year–40 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

OHSU

Portland, Oregon, 97239, United States

About this study

The purpose of this study is to learn more about counseling via telemedicine and advanced provision of medications to individuals at risk for pregnancy but before they are pregnant. If they experience this event, then they may subsequently have immediate access to the care they need plus an established connection with a health provider.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

18 to 40 years old at time of consent
Anatomically capable of pregnancy
Self-reported a history of regular menses (>24 and <38 days) in the past 3 years (other than during pregnancy)
Not currently pregnant and not desiring to be pregnant in the next year
Say they would seek to end the pregnancy if they became pregnant in the next year and who do not express a preference for an in office procedure
At-risk for unintended pregnancy defined as:
those who report being sexually active (vaginal sex with partners with sperm)
have not been told by a clinician that they cannot become pregnant
have not had a permanent contraception procedure and whose current sexual partner(s) has not had a permanent contraception procedure
who are not using a long-acting reversible contraceptive (LARC)
Willing and able to provide informed consent
Willing/able to receive phone calls from study staff and complete electronic surveys distributed by EMR or email
Planning to live within the state of Oregon or Washington for the 12 month study period.

Exclusion criteria

Less than 18 and older than 40 years old at the time of consent
Any medical contraindications to MAB (hemorrhagic disorder or will be taking anticoagulants during study period, chronic adrenal failure or will be taking long term corticosteroids >1 week during study period, inherited porphyria, or an allergy to mifepristone or misoprostol)
Currently pregnant or desiring pregnancy in the next year
State they would not seek to end a pregnancy if they became pregnant in the next year or who express a preference for an in office procedure
History of ectopic pregnancy

Treatment and study plan

Telehealth Visit

Other

telemedicine visit and follow-up surveys

Primary outcomes

The proportion of participants reporting confidence in key steps of taking medications

Time frame: Enrollment to 12 months

The proportion of participants reporting confidence in key steps of taking medications in follow-up surveys
Proportion of participants reporting satisfaction with the process

Time frame: Enrollment to 12 months

Proportion of participants reporting satisfaction with the process in follow up surveys

Sponsors and collaborators

Lead sponsor

Oregon Health and Science University

Other

Registry information

Important dates

Study start: 2023
Primary completion: 2025
Study completion: 2025
First posted: May 8, 2023
Registry last updated: Aug 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed